Propranolol inhibits the human ether-a-go-go-related gene potassium channels

European Journal of Pharmacology

Volumn 519, Issue 3, 2005, Pages 208-211

  Yao, Xiaozhou ^a   McIntyre, Maggie S ^a   Lang, Daniel G ^a   Song, Ivy H ^a   Becherer, James D ^a   Hashim, Mir A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

HERG (human ether a go go related gene); Propranolol; QTc interval prolongation

Indexed keywords

POTASSIUM CHANNEL HERG; PROPRANOLOL;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; GENETIC CODE; HEART REPOLARIZATION; IC 50; MOLECULAR MECHANICS; NONHUMAN; POTASSIUM CURRENT; PREDICTION; PRIORITY JOURNAL; QT PROLONGATION; VOLTAGE CLAMP; WHOLE CELL;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MEMBRANE POTENTIALS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS, VOLTAGE-GATED; PROPRANOLOL;

EID: 24644431912     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.05.010     Document Type: Article

References (12)

1. L. Borgstrom, C.G. Johansson, H. Larsson, and R. Lenander Pharmacokinetics of propranolol J. Pharmacokinet. Biopharm. 9 1981 419 429
2. C.E. Chiang, and D.M. Roden The long QT syndromes: genetic basis and clinical implications J. Am. Coll. Cardiol. 36 2000 1 12
3. F. Ducret, and P. Zech Deliberate self-overdose with propranolol Nouv. Presse Med. 7 1978 27 28
4. V. Farhangi, and R.A. Sansone QTc prolongation due to propranolol overdose Int. J. Psychiatry Med. 33 2003 201 202
5. E. Ficker, D. Thomas, P.C. Viswanathan, A.T. Dennis, S.G. Priori, C. Napolitano, M. Memmi, B.A. Wible, E.S. Kaufman, S. Iyengar, P.J. Schwartz, Y. Rudy, and A.M. Brown Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome Am. J. Physiol, Heart Circ. Physiol. 279 2000 H1748 H1756
6. O.P. Hamill, A. Marty, E. Neher, B. Sakmann, and F.J. Sigworth Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches Pflugers Arch. 391 1981 85 100
7. J.G. Hardman, and L.E. Limbird Goodman & Gilman's The Pharmacological basis of Therapeutics tenth ed. 2001 McGraw-Hill New York, NY
8. Z. Kopitar, B. Vrhova, A. Lenardic, P. Cvelbar, M. Zorz, and I. Francetic Dose-dependent bioavailability of propranolol Int. J. Clin. Pharmacol. Ther. Toxicol. 24 1986 319 322
9. J.R. Milne, A.J. Camm, D.E. Ward, and R.A. Spurrell Effect of intravenous propranolol on QT interval. A new method of assessment Br. Heart. J. 43 1980 1 6
10. W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. MacKenzie, S. Palethorpe, P.K. Siegl, I. Strang, A.T. Sullivan, R. Wallis, A.J. Camm, and T.G. Hammond Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc. Res. 58 2003 32 45
11. M.C. Sanguinetti, C. Jiang, M.E. Curran, and M.T. Keating A mechanistic link between an inherited and an acquired cardiac arrhythmia: hERG encodes the IKr potassium channel Cell 81 1995 299 307
12. S. Viskin Long QT syndromes and torsade de pointes Lancet 354 1999 1625 1633